Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page
- Check4 days agoChange DetectedNo substantive additions or deletions were detected in the study details; the page content remains the same.SummaryDifference0.0%

- Check11 days agoChange DetectedRevision: v3.4.2 is displayed on the page, indicating a minor site update. There are no observed changes to the study content, eligibility criteria, or navigation.SummaryDifference0.0%

- Check18 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0 on the page.SummaryDifference0.0%

- Check32 days agoChange DetectedThe update includes minor administrative changes: a new 'Show glossary' option and page revision to v3.4.0 with updated timestamps (Last Update Submitted that Met QC Criteria, Last Update Posted) and a No FEAR Act Data note.SummaryDifference0.3%

- Check39 days agoChange DetectedThe page now displays a new revision label Revision: v3.3.4 replacing v3.3.3, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check67 days agoChange DetectedAdded a Locations section with study sites in Indiana, New York, and Ohio; updated the page revision to v3.3.3.SummaryDifference0.4%

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.